These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19433554)

  • 1. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
    Baum EZ; Crespo-Carbone SM; Morrow BJ; Davies TA; Foleno BD; He W; Queenan AM; Bush K
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2785-90. PubMed ID: 19433554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
    Queenan AM; Shang W; Bush K; Flamm RK
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4092-7. PubMed ID: 20606064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
    Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L
    Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M; Mills JC; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.
    Singh M; Yau YCW; Wang S; Waters V; Kumar A
    Can J Microbiol; 2017 Dec; 63(12):929-938. PubMed ID: 28922614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
    Islam S; Jalal S; Wretlind B
    Clin Microbiol Infect; 2004 Oct; 10(10):877-83. PubMed ID: 15373880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlorhexidine leads to the evolution of antibiotic-resistant Pseudomonas aeruginosa.
    Tag ElDein MA; Yassin AS; El-Tayeb O; Kashef MT
    Eur J Clin Microbiol Infect Dis; 2021 Nov; 40(11):2349-2361. PubMed ID: 34169445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.
    Dean CR; Visalli MA; Projan SJ; Sum PE; Bradford PA
    Antimicrob Agents Chemother; 2003 Mar; 47(3):972-8. PubMed ID: 12604529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.
    Wolter DJ; Smith-Moland E; Goering RV; Hanson ND; Lister PD
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):43-50. PubMed ID: 15380277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.
    Peña C; Suarez C; Tubau F; Juan C; Moya B; Dominguez MA; Oliver A; Pujol M; Ariza J
    J Clin Microbiol; 2009 Aug; 47(8):2381-7. PubMed ID: 19494059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis.
    Chuanchuen R; Wannaprasat W; Ajariyakhajorn K; Schweizer HP
    Microbiol Immunol; 2008 Aug; 52(8):392-8. PubMed ID: 18667038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa.
    Muller C; Plésiat P; Jeannot K
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1211-21. PubMed ID: 21149619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
    Drusano GL; Bonomo RA; Bahniuk N; Bulitta JB; Vanscoy B; Defiglio H; Fikes S; Brown D; Drawz SM; Kulawy R; Louie A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):231-42. PubMed ID: 22005996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of carbapenem-resistant but cephalosporin-susceptible
    Khalili Y; Yekani M; Goli HR; Memar MY
    Acta Microbiol Immunol Hung; 2019 Dec; 66(4):529-540. PubMed ID: 31707785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycoside resistance in
    Thacharodi A; Lamont IL
    J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708991
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.
    Llanes C; Hocquet D; Vogne C; Benali-Baitich D; Neuwirth C; Plésiat P
    Antimicrob Agents Chemother; 2004 May; 48(5):1797-802. PubMed ID: 15105137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Vettoretti L; Plésiat P; Muller C; El Garch F; Phan G; Attrée I; Ducruix A; Llanes C
    Antimicrob Agents Chemother; 2009 May; 53(5):1987-97. PubMed ID: 19258280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.